Business Wire

IQM

9.12.2021 17:02:06 CET | Business Wire | Press release

Share
IQM: A New Super-cooled Microwave Source Boosts the Scale-up of Quantum Computers

In a new work published in Nature Electronics, researchers in Finland have developed a circuit that produces the high-quality microwave signals required to control quantum computers while operating at temperatures near absolute zero. This is a key step towards moving the control system closer to the quantum processor, which may make it possible to greatly increase the number of qubits in the processor.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209005593/en/

One of the factors limiting the size of quantum computers is the mechanism used to control the qubits in quantum processors. This is normally accomplished using a series of microwave pulses, and because quantum processors operate at temperatures near absolute zero, the control pulses are normally brought into the cooled environment via broadband cables from room temperature.

As the number of qubits grows, so does the number of cables needed. This limits the potential size of a quantum processor, because the refrigerators cooling the qubits would have to become larger to accommodate more and more cables while also working harder to cool them down – ultimately a losing proposition.

A research consortium including Aalto University , VTT Technical Research Centre of Finland , and IQM Quantum Computers has now developed a key component of the solution to this conundrum. ‘We have built a precise microwave source that works at the same extremely low temperature as the quantum processors, approximately -273 degrees,’ says the team leader Mikko Möttönen , Professor at Aalto University and VTT Technical Research Centre of Finland and a Co-Founder and Chief Scientist of IQM.

The new microwave source is an on-chip device that can be integrated with a quantum processor. Less than a millimetre in size, it potentially removes the need for high-frequency control cables connecting different temperatures. With this low-power, low-temperature microwave source, it may be possible to use smaller cryostats while still increasing the number of qubits in a processor.

‘Our device produces one hundred times more power than previous versions, which is enough to control qubits and carry out quantum logic operations,’ says Möttönen. ‘It produces a very precise sine wave, oscillating over a billion times per second. As a result, errors in qubits from the microwave source are very infrequent, which is important when implementing precise quantum logic operations.’

However, a continuous-wave microwave source, such as the one produced by this device, cannot be used as is to control qubits. First, the microwaves must be shaped into pulses. The team is currently developing methods to quickly switch the microwave source on and off.

Even without a switching solution to create pulses, an efficient, low-noise, low-temperature microwave source could be useful in a range of quantum technologies, such as quantum sensors.

‘In addition to quantum computers and sensors, the microwave source can act as a clock for other electronic devices. It can keep different devices in the same rhythm, allowing them to induce operations for several different qubits at the desired instant of time,’ explains Möttönen.

The theoretical analysis and the initial design were carried out by Juha Hassel and others at VTT. Hassel, who started this work at VTT, is currently the head of engineering and development at IQM Quantum Computers, Pan-European leader in quantum computers. The device was then built at VTT and operated by postdoctoral research Chengyu Yan and his colleagues at Aalto University using the OtaNano research infrastructure. Yan is currently an associate professor at Huazhong University of Science and Technology, China. The teams involved in this research are part of the Academy of Finland Centre of Excellence in Quantum Technology (QTF) and the Finnish Quantum Institute (InstituteQ).

Original research paper

Chengyu Yan, Juha Hassel, Visa Vesterinen, Jinli Zhang, Joni Ikonen, Leif Grönberg, Jan Goetz and Mikko Möttönen, A low-noise on-chip coherent microwave source , Nature Electronics, DOI:10.1038/s41928-021-00680-z (2021)

https://doi.org/10.1038/s41928-021-00680-z (link opens after embargo ceases)

Preprint available at any time: https://arxiv.org/pdf/2103.07617

More pictures in the material bank : https://materialbank.aalto.fi/l/sjcg87sHxFfR

About IQM Quantum Computers

IQM is a Pan-European leader in quantum computers.

IQM provides on-site quantum computing for research labs and supercomputing data centers and offers full access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique application-specific co-design approach.

IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is building Germany’s quantum computer that will be integrated into an HPC supercomputer to create an accelerator for future scientific research. IQM has offices in Bilbao, Munich and Espoo and employs over 130 people. More information: www.meetiqm.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye